Robert Gould, Director, Novel Therapeutics, Broad Institute
Dr. Gould is currently Director, Novel Therapeutics, The Broad Institute of MIT and Harvard. The Institute is a research collaboration involving faculty, professional staff and students from throughout the MIT and Harvard academic and medical communities and is governed jointly by the two universities. It was founded in 2003 through the far-sighted generosity of philanthropists Eli and Edythe Broad. The Broad Institute's mission is to empower creative scientists to construct new powerful tools for genomic medicine, to make them accessible to the global scientific community, and to apply them to the understanding and treatment of disease. The Novel Therapeutics platform, formed in December 2006, is designed to achieve the last of these goals.
Gould retired from Merck Research Labs in 2006 where he was Vice President, Licensing and External Research. For the three years prior to that position he was Vice President, Basic Research, Merck Research Labs, in Pennsylvania where he oversaw strategic direction and drug discovery activities for multiple therapeutic areas, as well as MRL's centralized high throughput screening and imaging facilities. In three years approximately 20 compounds in 7 different therapeutic areas entered into further development.
Dr. Gould obtained degrees from Spring Arbor College , Michigan (1976) and The University of Iowa (1981). After post-doctoral studies at The Johns Hopkins University, Maryland, he joined Merck Sharp and Dohme Research Labs where he remained until retiring and joining the Broad Institute. Dr. Gould has published over 90 peer-reviewed publications and 16 patents.
